Abstract
Patient-reported outcomes (PROs) represent an important evaluation of health-related quality of life that has become more commonly incorporated into oncology drug clinical trials. The frequency of PRO inclusion as an endpoint in oncology drug clinical trials leading to the initial accelerated approval of a new therapy is not yet known. We conducted a cross-sectional study evaluating all new drug applications submitted to the FDA over the past 10 years (2013–2022) that led to the initial approval of an oncology drug through the accelerated approval process. The objective was to assess whether the trials leading to such an approval included PROs. Between 2013 and 2022, the FDA approved 59 unique drugs for an oncology indication via the accelerated approval pathway, and 35 (59%) included a PRO assessment in the clinical trial. A median of 1 PRO measurement was used in each trial, with 23 different types of PRO assessment tools were used across the 59 new drug applications. In summary, we found that PRO measurements are inconsistently utilized in trials leading to initial accelerated approval of oncology drugs, and there seems to be a lack of harmonization of different PRO measurement tools used across trials.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Beaver JA, Howie LJ, Pelosof L et al (2018) A 25-year experience of US Food and Drug Administration accelerated approval of malignant hematology and oncology drugs and biologics: a review. JAMA Oncol 4(6):849–856
Basch E (2018) Patient-reported outcomes: an essential component of oncology drug development and regulatory review. Lancet Oncol 19(5):595–597
U.S. Department of Health and Human Services Food and Drug Administration. Core patient-reported outcomes in cancer clinical trials: guidance for industry, draft guidance. June 2021. Available at: www.fda.gov/media/149994/download. Accessed 24 Aug 2023
EQUATOR Network. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies
Food and Drug Administration. Drugs@FA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed 15 Apr 2023
Cella D, Chen CI, Quek RGW et al (2022) Patient-reported outcomes labeling for oncology drugs: multidisciplinary perspectives on current status and future directions. Front Pharmacol 17(13):1031992
Ge C, Guo K, Li Y et al (2023) Analysis of patient-reported outcomes in the approval of novel oncology drugs in the United States, 2017-2022. EClinicalMedicine. 59:101953
Pe M, Alanya A, Falk RS et al (2023) Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints in Cancer Clinical Trials–Innovative Medicines Initiative (SISAQOL-IMI): stakeholder views, objectives, and procedures. Lancet Oncol 25(6):e270–e283
Roydhouse JK, Fiero MH, Kluetz PG (2019) Investigating potential bias in patient-reported outcomes in open-label cancer trials. JAMA Oncol 5(4):457–458
Gnanasakthy A, Russo J, Gnanasakthy K et al (2022) A review of patient-reported outcome assessments in registration trials of FDA-approved new oncology drugs (2014-2018). Contemp Clin Trials 120:106860
Liu L, Choi J, Musoro JZ et al (2023) Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice. Lancet Oncol 24:e197–e206
Basch E, Campbell A, Hudgens S, et al. Broadening the definition of tolerability in cancer clinical trials to better measure the patient experience. A Friends of Cancer Research White Paper. Available at https://friendsofcancerresearch.org/wp-content/uploads/Comparative-Tolerability-Whitepaper_FINAL.pdf. Accessed 20 Sept 2023
Parikh RB, Hubbard RA, Wang E et al (2023) Exposure to US cancer drugs with lack of confirmed benefit after US Food and Drug Administration accelerated approval. JAMA. Oncol. Feb 23:e227770
Ciani O, Meregaglia M, De Lorenzo F et al (2023) Patient-reported outcome measures in oncology drugs approved by the European Medicines Agency, 2017-2021. JAMA Netw Open 6(1):e2251564
Author information
Authors and Affiliations
Contributions
All authors were involved with the conceptualization of the manuscript. D.C.M. and J.B.E. collected and analyzed the data. D.C.M. wrote the main manuscript text and prepared Table 1. All authors reviewed the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Moore, D.C., Elmes, J.B., Strassels, S.A. et al. Use of patient-reported outcome measures for oncology drugs receiving accelerated approval. Support Care Cancer 31, 602 (2023). https://doi.org/10.1007/s00520-023-08068-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00520-023-08068-9